If your doctor prescribes a GLP-1 medication for weight loss but your insurance won't cover it, you have options.

Telehealth companies offer lifestyle support so people taking obesity drugs can have the most success losing weight. But employers also want the telehealth providers to limit spending on the drugs.

Millions of people with Medicare will soon be eligible to get discounted GLP-1 drugs for weight loss. Here's how it will work.

Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, according to an analysis by GoodRx, a drug discount website.

A majority of people who start the obesity and diabetes medicines known as GLP-1s also quit them, and plan to restart again. Research hasn't yet shown the health impacts of cycling on and off the drugs.

Big food companies are starting to market to people on the powerful new obesity meds with labels that say "GLP-1 Friendly." Nutritionists help us decode that message.

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now.

Drugmaker Novo Nordisk said the prescription medicine can be found at a range of pharmacies, including CVS and Costco, as well as some telehealth providers.

Medicare announced 15 lower drugs after a second round of negotiations with pharmaceutical companies. The drugs include Ozempic and also drugs to treat asthma, breast cancer and leukemia.

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.

Weight-loss drugs like Wegovy and Zepbound often cause nausea and other side effects. Brain scientists are looking for ways to solve this problem.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some limitations.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, others are continuing and pushing regulatory boundaries. 

Former FDA chief Dr. David Kessler says the new weight-loss drugs are a powerful tool to fight obesity. But they come with pitfalls. Here's his tips for how to use them successfully.